Literature DB >> 9481909

[Fatalities caused by anticholinergic antiparkinsonian drugs. Analysis of findings in a 11-year national material].

P Gjerden1, K S Engelstad, G Pettersen, L Slørdal.   

Abstract

All autopsy samples received at the National Institute of Forensic Toxicology during the years 1986-1996 which contained anticholinergic antiparkinsonian drugs were reviewed. Of a total of 69 cases, orphenadrine was present in 57 (83%), biperiden in 8 (12%), procyclidine in 3 (4%), and trihexyphenidyl/benzhexol in 1 (1%) of the subjects. The measured concentrations were assessed in light of previously published data. Of 21 cases where causality between drug ingestion and death was classified as either highly probable (18/21) or possible (3/21), all subjects tested positive for orphenadrine. In the autopsy samples from these patients, orphenadrine concentrations in the 4.5-600 mumol/l range (mean 62.5 mumol/l, SD 126.5 mumol/l) were determined. Because of a low national autopsy rate, there is reason to believe that the actual numbers of drug-related deaths in this period may have been significantly higher. It is concluded that orphenadrine is responsible for a disproportionally high number of overdose deaths.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9481909

Source DB:  PubMed          Journal:  Tidsskr Nor Laegeforen        ISSN: 0029-2001


  3 in total

1.  The use of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal of orphenadrine.

Authors:  Pål Gjerden; Lars Slørdal; Jørgen G Bramness
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

2.  Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo.

Authors:  D Pubill; E Verdaguer; A M Canudas; F X Sureda; E Escubedo; J Camarasa; M Pallàs; A Camins
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

3.  The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study.

Authors:  Pål Gjerden; Jørgen G Bramness; Lars Slørdal
Journal:  Br J Clin Pharmacol       Date:  2008-12-16       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.